PP-C8

• Description :

  PP-C8 is a potent and selective PROTAC CDK12-Cyclin K degrader. PP-C8 induces CDK12-Cyclin K degradation with DC50s of 416 and 412 nM for CDK12 and Cyclin K, respectively. PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC) [1].

• UNSPSC :

  12352005

• Target :

  CDK; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PROTAC

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pp-c8.html

• Purity :

  99.99

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CC(N1C=NC2=C1N=C(N=C2NCC3=NC4=CC(F)=C(C=C4N3)NCCCCCCCCNC(COC5=C6C(N(C(C6=CC=C5)=O)C7CCC(NC7=O)=O)=O)=O)N8CCOCC8)C

• Molecular Formula :

  C43H51FN12O7

• Molecular Weight :

  866.94

• References & Citations :

  [1]Tian Niu, et al. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. Eur J Med Chem. 2022 Jan 15;228:114012.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3032108-74-7]